Table 2 Cox regression analysis of favorable treatment response in HBeAg-positive patients without drug resistance (n = 100).

From: Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

Variable

HBV DNA undetectable

HBeAg seroconversion

Univariate

Multivariate

Univariate

Multivariate

Hazard ratio

P-value

Hazard ratio

P-value

Hazard ratio

P-value

Hazard ratio

P-value

(95% CI)

(95% CI)

(95% CI)

(95% CI)

Sex (Male = 1. Female = 0)

1.184 (0.750–1.870)

0.469

  

1.404 (0.753–2.615)

0.286

  

Age (years)

1.003 (0.982–1.024)

0.787

  

1.002 (0.974–1.030)

0.897

  

ALT (U/L)

1.003 (1.001–1.004)

<0.001

1.002 (1.000–1.004)

0.016

1.002 (1.001–1.004)

0.005

1.002 (1.000–1.004)

0.041

HBV DNA (Log10 IU/mL)

0.753 (0.640–0.886)

<0.001

0.826 (0.675–1.011)

0.064

0.910 (0.740–1.120)

0.375

  

HBsAg (Log10 IU/mL)

0.636 (0.524–0.773)

<0.001

0.776 (0.592–1.018)

0.067

0.729 (0.569–0.934)

0.012

0.733 (0.558–0.962)

0.025

Drug (ETV = 1, LAM = 0)

2.124 (1.233–3.659)

0.007

2.347 (1.321–4.168)

0.004

0.633 (0.342–1.171)

0.145

  

Primary treatment failure* (Yes = 1, No = 0)

0.041 (0.001–1.771)

0.096

  

0.046 (0.000–20.959)

0.323

  

IgG-G0F >30% (Yes = 1, No = 0)

3.358 (2.075–5.433)

<0.001

3.071 (1.835–5.141)

<0.001

2.823 (1.426–5.589)

0.003

2.034 (1.011–4.093)

0.046

HBeAg seroconversion (Yes = 1, No = 0)

2.369 (1.507–3.724)

<0.001

1.688 (1.024–2.783)

0.040

    
  1. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; ETV, entecavir; G0F, agalactosylation with core fucosylation; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; LAM, lamivudine. Primary treatment failure refers to the inability of the antiviral agent to reduce serum HBV DNA by ≧1 log10 IU/ml within the first six months of treatment. *Only detected in the lamivudine group.
Back to article page